Control of Assistive Devices Via Brain-Computer Interface Technology
Launched by NEURALINK CORP · Nov 26, 2024
Trial Information
Current as of June 27, 2025
Enrolling by invitation
Keywords
ClinConnect Summary
No description provided
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • Continued enrollment in the PRIME Study.
- • Implanted with the N1 Implant.
- Exclusion Criteria:
- • Explantation or deactivation of the N1 Implant.
- • Insufficient N1 Implant BCI performance demonstrated.
- • Lack of a suitable physical space to perform research sessions.
- • Any condition which, in the opinion of the Investigator, would compromise the candidate's ability to safely participate in the study.
About Neuralink Corp
Neuralink Corp. is an innovative neurotechnology company focused on developing advanced brain-machine interface (BMI) systems to enhance human cognitive capabilities and address neurological disorders. Founded by Elon Musk and a team of leading engineers and neuroscientists, Neuralink aims to create seamless communication pathways between the human brain and external devices. The company is dedicated to conducting rigorous clinical trials to explore the safety and efficacy of its cutting-edge technologies, with the ultimate goal of revolutionizing treatments for conditions such as paralysis, memory loss, and other neurodegenerative diseases. Through its pioneering research and commitment to ethical practices, Neuralink seeks to push the boundaries of neuroscience and improve the quality of life for individuals with neurological impairments.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Phoenix, Arizona, United States
Patients applied
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported